Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece
Expert Review of Pharmacoeconomics & Outcomes Research · 15.03.2024 · 24 (3) · 375-385
DOI: 10.1080/14737167.2023.2288249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 25.11.2023. Verfasst von George Gourzoulidis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Through Evidence, Athens, Greece. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pyrimidines, Aminopyridines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Pfizer Hellas.
Abstract (Originalsprache)
OBJECTIVES: To evaluate the cost-effectiveness of lorlatinib compared to 1st generation anaplastic lymphoma kinase (ALK) TKI crizotinib, and 2nd generation TKIs alectinib and brigatinib, for previously untreated patients with ALK+ advanced Non-Small Cell Lung Cancer (aNSCLC). METHODS: A partitioned survival model was locally adapted from a Greek payer perspective over a lifetime horizon. Clinical, safety and utility data were extracted from literature. Direct medical costs reflecting the year 2023 were included in the analysis (€). Model outcomes were patients' life years (LYs), quality-adjusted life years (QALYs), total costs and incremental cost-effectiveness ratios (ICERs). RESULTS: Total cost per patient with lorlatinib, alectinib, crizotinib, and brigatinib was estimated to be €188,205, €183,343, €75,028, and €145,454 respectively. Lorlatinib appeared to yield more LYs and QALYs gained versus alectinib, crizotinib, and brigatinib. Hence, lorlatinib resulted in ICERs of €4,315 per LY gained and €4,422 per QALY gained compared to alectinib, €34,032 per LY gained and €48,256 per QALY gained versus crizotinib and €16,587 per LY gained and €26,271 per QALY gained compared to brigatinib. CONCLUSION: Lorlatinib provides substantial clinical benefit and appears to be a cost - effective treatment option compared to 1st and 2nd generation TKIs for previously untreated patients with ALK+ aNCSLC in Greece.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Through Evidence, Athens, Greece.
- Pfizer Hellas, Athens, Greece.
ORCID-Profile: George Gourzoulidis
Förderung
- Pfizer Hellas
Zitieren
APA
Gourzoulidis, G., Zisimopoulou, O., Liavas, A., & Tzanetakos, C. (2024). Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece. Expert Review of Pharmacoeconomics & Outcomes Research, 24(3), 375-385. https://doi.org/10.1080/14737167.2023.2288249
Vancouver
Gourzoulidis G, Zisimopoulou O, Liavas A, Tzanetakos C. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece. Expert Review of Pharmacoeconomics & Outcomes Research. 2024;24(3):375-385. doi:10.1080/14737167.2023.2288249
BibTeX
@article{Gourzoulidis2024,
author = {Gourzoulidis, George and Zisimopoulou, Oresteia and Liavas, Andrianos and Tzanetakos, Charalampos},
title = {Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2024},
volume = {24},
number = {3},
pages = {375--385},
doi = {10.1080/14737167.2023.2288249}
}
EUVIMED